The renovated 1880s manse, built by one of the Pfizer co-founders, boasts plasterwork, mantels, stained glass, and an ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...

Claims on social media suggest Pfizer's COVID vaccine has fatal side effects, referencing a US House document. However, the report includes adverse events, not side effects. Adverse events ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 ...

Pfizer generated strong growth last year despite a significant drop in COVID revenue. The company's business is solid, and its growth prospects are encouraging. Investors, however, remain ...